Publications by authors named "M J Vivancos"
Background: Despite effective antiretroviral therapy, people with HIV (PWH) experience persistent systemic inflammation and increased morbidity and mortality. Modulating the gut microbiome through fecal microbiota transplantation (FMT) represents a novel therapeutic strategy. We aimed to evaluate proteomic changes in inflammatory pathways following repeated, low-dose FMT versus placebo.
View Article and Find Full Text PDFDespite remarkable improvement in the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) care continuum, the rate of late diagnosis of HIV and HCV in high-income countries remains unacceptably high. Testing relies mainly on primary care physicians' identification of risk factors. We aimed to adapt an analogic to an online questionnaire to help HIV and HCV screening and perform a pilot study to assess its accuracy and acceptability.
View Article and Find Full Text PDFBackground: Non-AIDS defining malignancies present a growing challenge for persons with HIV (PWH), yet tailored interventions for timely cancer diagnosis are lacking. The Spanish IMPAC-Neo protocol was designed to compare two comprehensive cancer screening strategies integrated into routine HIV care. This study reports baseline data on the prevalence and types of precancerous lesions and early-stage cancer among participants at enrolment.
View Article and Find Full Text PDFArticle Synopsis
- The study examined improvements in the HIV care continuum in Spain from 2005 to 2022, focusing on the time taken for patients to progress through different stages of care, including linkage to care, initiation of antiretroviral therapy (ART), and achieving viral suppression.
- Over the years, significant reductions were observed in the time taken for these transitions, with linkage to care decreasing from 6.0 weeks to 1.3 weeks and ART initiation dropping from 15.9 weeks to 0.4 weeks.
- Despite these advancements, a rise in late diagnoses was noted, increasing from 38.6% to 46.4% post-2012, highlighting the ongoing challenge of ensuring timely diagnosis in the effort to
Objective: Multiple strategies have been utilised to reduce the incidence of HIV, including PrEP and rapid antiretroviral therapy initiation. The study objectives were to evaluate the efficacy, safety, satisfaction, treatment adherence, and system retention obtained with rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in naïve patients.
Methods: This phase IV, multicenter, open-label, single-arm, 48-week clinical trial enrolled patients between January 2020 and June 2022.